<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231004059613N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-16</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of psychological interventions on imposter syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of psychological interventions on imposter syndrome  in teenager girl</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72954</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: The samples are divided into intervention and control groups, and the intervention group receives training sessions, but the control group does not receive information during the study, Randomization description: The sampling method of the study is cluster type. First, the names of the girls' schools in the two districts of Lar city, which include the old city and the new city, are written on separate papers by a collaborator who is not aware of the study and samples. Then, the names of the schools in the Old City area are written on paper and placed in a sealed envelope, and the names of the girls' schools in the New City area are also written separately on paper and kept in a sealed envelope. In this way, we divide into two clusters. Then, by the same colleague, who is not aware of the type of study, the names of two schools are removed from the envelope of old city district cluster and the names of two schools from the envelope of new city district cluster. At the same time, the names removed without knowing the name are put into the sealed envelope of the dipper and two names are removed from the basket in a simple random manner, the first two schools are selected as the control group and the next two schools are selected as the intervention group, Blinding description: Person who performs data analysis and statistical analysis blinded to the study, data and samples. In this way, this person does not know the names and characteristics of the samples, and the names are separated from the questionnaires and the questionnaires are coded, and the speech analyzer is aware of the objectives of the study.</study_design>
      <phase>3</phase>
      <hc_freetext>Imposter syndrome.</hc_freetext>
      <i_freetext>Intervention 1: For the intervention group, 8 training sessions, which include the training of cognitive-behavioral approaches, are provided for 2 months and one hour per week. Summary of the sessions: 1- The first session: getting to know and identify the people of the group and stating the purpose of forming the group and introducing and stating the rules and principles governing the meetings and introducing the imposter syndrome, signs and ways of coping. 2- The second session: introducing cognitive behavioral approaches and applications This approach. 3- The third session: teaching the multidimensional relationship between thinking, behavior and emotions. 4- The fourth session: Increasing self-awareness and self-introduction and defining and identifying one's own thoughts. 5- The fifth session: Talking about strengths and Each person's weakness to strengthen awareness and fundamental beliefs 6-Sixth session: Introduction of cognitive errors and concrete daily examples of each person and the effect of cognitive errors on thoughts and feelings 7-Seventh session: Learning to recognize the vertical arrow method. Drawing by each person. 8-Eighth session: Teaching the method of illustration and summarizing all sessions. Intervention 2: Control group: In this study, there is no intervention in the control group. After the end of the intervention sessions, an educational pamphlet containing the content of the sessions will be given to the control group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After completing the study, the coded questionnaires can be shared without the details of the samples and after de-identifying the participants.

When:
The access period starts 6 months after the results are published.

To whom:
Shiraz University of Medical Sciences and Lar Department of Education and schools participating in the study have permission to send requests for access to documents.

Conditions:
The data can be used for future studies as well as testing other methods and treatments for this syndrome and solving this disorder. In addition, the condition of the collection of these data is the consent of the samples, the main researcher, Shiraz University of Medical Sciences and the General Directorate of Education of Larestan.

Where to obtain:
Clients can refer to the General Department of Education of Larestan or Shiraz University of Medical Sciences to receive documents. Larestan Breeding Education Address: LAR, Shahr Jadid, Mahart Blvd., Contact Number: 07152244500- Shiraz University of Medical Sciences Research and Technology Support: Zand St., in front of Palestine St., Shiraz University of Medical Sciences, Central Building, Contact No.: 07132301054

How to obtain:
First, the applicant writes a letter under the title of permission to access the data without personal information of the samples, stating the reason for the need for the data, and refers to the Vice-Chancellor for Research and Information Technology of Shiraz University of Medical Sciences, and after reviewing the letter by the organization and permission from The main researcher will give a letter of consent from the Department of Education to the applicant, and after going through the administrative procedures, permission will be issued at the discretion of the deputy.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Shahrazad Yektatab</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz, Falke Namazi, Namazi Hospital, Fatemeh College of Nursing and Midwifery</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1311971936</zip>
        <telephone>+98 71 3647 4254</telephone>
        <email>yektash@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Shahrazad Yektatab</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz, Falke Namazi, Namazi Hospital, Fatemeh College of Nursing and Midwifery</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7193613119</zip>
        <telephone>071364474254</telephone>
        <email>yektash@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>It includes students who are girls and study in the twelfth grade
Students who score higher than 60 in the imposter syndrome questionnaire
The family and the teenager herself must sign the informed consent form to participate in the study</inclusion_criteria>
      <agemin>17 years</agemin>
      <agemax>18 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Students who do not want to continue cooperating in the project for any reason at any stage of the research
Students suffering from chronic physical or mental diseases according to their own statement and the health file available in the school
People who have not completed the questionnaire completely</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F98</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other behavioral and emotional disorders with onset usually occurring in childhood and adolescence</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>For the intervention group, 8 training sessions, which include the training of cognitive-behavioral approaches, are provided for 2 months and one hour per week. Summary of the sessions: 1- The first session: getting to know and identify the people of the group and stating the purpose of forming the group and introducing and stating the rules and principles governing the meetings and introducing the imposter syndrome, signs and ways of coping. 2- The second session: introducing cognitive behavioral approaches and applications This approach. 3- The third session: teaching the multidimensional relationship between thinking, behavior and emotions. 4- The fourth session: Increasing self-awareness and self-introduction and defining and identifying one's own thoughts. 5- The fifth session: Talking about strengths and Each person's weakness to strengthen awareness and fundamental beliefs 6-Sixth session: Introduction of cognitive errors and concrete daily examples of each person and the effect of cognitive errors on thoughts and feelings 7-Seventh session: Learning to recognize the vertical arrow method. Drawing by each person. 8-Eighth session: Teaching the method of illustration and summarizing all sessions</i_keyword>
      <i_keyword>Control group: In this study, there is no intervention in the control group. After the end of the intervention sessions, an educational pamphlet containing the content of the sessions will be given to the control group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Imposter syndrome. Timepoint: Measuring the primary outcome at the beginning of the study (before the start of the intervention) and after the end of the eight sessions of the intervention (2 months after the start of the intervention). Method of measurement: Clance Imposter Phenomenon Scale (1978).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-04</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>6th Floor,  Administration Building of Shiraz University of Medical Sciences  Zand St., Shiraz, Iran Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
